Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

3.530 -0.900 (-20.32%)

Streaming Delayed Price Updated: 11:41 AM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

December 27, 2023

From Enveric Biosciences

Via Business Wire

5 Biotech stocks tapping into unmet mental health treatment needs

December 20, 2023

Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.

Via MarketBeat

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

December 20, 2023

From Enveric Biosciences

Via Business Wire

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

December 05, 2023

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

November 29, 2023

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

November 27, 2023

From Enveric Biosciences

Via Business Wire

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

November 24, 2023

From Enveric Biosciences

Via Business Wire

Enveric Biosciences' Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials ↗

November 14, 2023

Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its...

Via Benzinga

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

November 13, 2023

From Enveric Biosciences, Inc.

Via Business Wire

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Enveric Biosciences to Present at the Centurion One 5th Global Summit

October 20, 2023

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders

October 18, 2023

From Enveric Biosciences

Via Business Wire

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit

October 11, 2023

From Enveric Biosciences

Via Business Wire

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 04, 2023

Via Benzinga

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates

October 03, 2023

From Enveric Biosciences

Via Business Wire

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry

September 27, 2023

From Enveric Biosciences

Via Business Wire

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 21, 2023

Via Benzinga

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here ↗

September 21, 2023

The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its...

Via Benzinga

Topics Derivatives Intellectual Property

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

September 20, 2023

From Enveric Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.